Strategic partnerships Active IND in the US and CTA in Canada for BTM-3566, plus recent academic collaborations with the University of Illinois Chicago and Illinois Institute of Technology present ready-made channels for co-development, clinical research support, or sponsored trials to accelerate regulatory progress.

Clinical focus Lead candidate targets mature B-cell lymphomas (MCL, DLBCL, FL) with preclinical evidence of activity including tumor regression and overcoming CAR-T resistance, offering a clear outpatient-ready path for investigator-initiated trials and potential Phase I/II collaborations.

Expansion potential Plan to extend development from hematologic malignancies into solid tumors broadens addressable market and creates multiple entry points for partnerships in oncology CROs, pharma co-development deals, and licensing conversations.

Financial signal Seed funding and ongoing operations with modest revenue and a total funding base around twenty-five million indicate a growth-stage partner profile receptive to milestone-based collaborations, co-funding, or strategic investments.

Technology & storytelling Mitochondrial dynamics as a novel mechanism offers a differentiator for collaboration proposals, with the potential to align with biotech investors and pharma interest in first-in-class oncology therapeutics and biomarkers connected to mitochondrial pathways.